AC
NBIX icon

Athanor Capital’s Neurocrine Biosciences NBIX Stock Holding History

Athanor Capital’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-12,022
Closed -$1.15M – 971
2020
Q4 		$1.15M Sell
12,022
-14,296
-54% -$1.38M 0.03% 281
2020
Q3 		$2.53M Buy
26,318
+11,865
+82% +$1.37M 0.1% 115
2020
Q2 		$1.76M Buy
+14,453
New +$1.6M 0.09% 124
2020
Q1 		– Sell
-13,000
Closed -$1.4M – 278
2019
Q4 		$1.4M Buy
13,000
+1,900
+17% +$199K 0.06% 133
2019
Q3 		$1M Buy
+11,100
New +$1.04M 0.06% 118

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Athanor Capital's NBIX Position: Q1 2021 in Review

Athanor Capital sold out of Neurocrine Biosciences (NBIX) in Q1 2021, closing a stake of 12,022 shares — an estimated $1.15M sold.

Athanor Capital first reported a position in NBIX in Q3 2019 and held it in 5 quarters. The position peaked at $2.53M in Q3 2020. 419 funds tracked by Wall St. Rank hold NBIX as of Q1 2021.

  • Athanor Capital reported no remaining Neurocrine Biosciences position as of Q1 2021 after selling out during the quarter.
  • Athanor Capital sold 12,022 Neurocrine Biosciences shares in Q1 2021, an estimated $1.15M.
  • Athanor Capital first reported a position in Neurocrine Biosciences in Q3 2019 and held it in 5 quarters.
  • Athanor Capital's Neurocrine Biosciences position peaked at $2.53M in Q3 2020.
  • 419 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2021.

Based on Athanor Capital's 13F filing for Q1 2021, filed 14 May 2021.